EC
BEAM icon

Euclidean Capital’s Beam Therapeutics BEAM Stock Holding History

Euclidean Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-31,131
Closed -$4.01M – 11
2021
Q2 		$4.01M Hold
31,131
– – 1.3% 12
2021
Q1 		$2.49M Buy
+31,131
New +$2.96M 0.83% 10

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Euclidean Capital's BEAM Position: Q3 2021 in Review

Euclidean Capital sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 31,131 shares — an estimated $4.01M sold.

Euclidean Capital first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $4.01M in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Euclidean Capital reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Euclidean Capital sold 31,131 Beam Therapeutics shares in Q3 2021, an estimated $4.01M.
  • Euclidean Capital first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Euclidean Capital's Beam Therapeutics position peaked at $4.01M in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Euclidean Capital's 13F filing for Q3 2021, filed 15 Nov 2021.